A Commercial Stage Biopharmaceutical Company Focused On The Development And Commercialisation Of Diagnostic Therapeutic Radiopharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from A commercial stage biopharmaceutical company focused on the development and commercialisation of diagnostic therapeutic radiopharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In A Commercial Stage Biopharmaceutical Company Focused On The Development And Commercialisation Of Diagnostic Therapeutic Radiopharmaceuticals Today - Breaking & Trending Today

Telix to Present at Jefferies London Healthcare Conference 2022

MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company),a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that Dr Christian Behrenbruch, Group CEO and Managing Director, will be presenting at the Jefferies London Healthcare Conference 2022. The presentation will take place on Thursday 17 November from 3:15 - 3:45pm GMT (10:15 - 10:45am EST / 2:15 - 2:45am AEDT, 18 Nov). A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff255/tlx/1728648 The webcast will be accessible on demand on the Telix website following the event. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United ....

United States , Kyahn Williamson , Christian Behrenbruch , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Australian Therapeutic Goods Administration , Corporate Communications , Telix Pharmaceuticals Limited , Health Canada , Managing Director , Jefferies London Healthcare Conference , Group Chief Executive , Nov 11 , 022 Prnewswire Telix Pharmaceuticals Limited Asx Tlx , The Company , A Commercial Stage Biopharmaceutical Company Focused On The Development And Commercialisation Of Diagnostic Therapeutic Radiopharmaceuticals , Dvises That Dr Christian Behrenbruch , Group Ceo And Managing Director , Ill Be Presenting At The Jefferies London Healthcare Conference 2022 Presentation Will Take Place On Thursday 17 November From 3 15 45pm Gmt 10 45am Est 2 Aedt , 8 Nova Live Webcast Of The Presentation Will Be Available At Following Link Https Wsw Com Jeff255 Tlx 1728648 Accessible On Demand Telix Website Event About Pharmaceuticals Limited Isa Biopharmaceutical Company Focused Development And Commercialisation Diagnostic Therapeutic Radiopharmaceuticals Is Headquartered In Melbourne , Ustralia With International Operations In The United States , Urope Belgium And Switzerland , Nd Japan Telix Is Developinga Portfolio Of Clinical Stage Products That Aims To Address Significant Unmet Medical Need In Oncology And Rare Diseases Listed On The Australian Securities Exchange Asx Tlx For More Information Visit Www Telixpharma Comand Follow Twitter Linkedin 39s Lead Product , Allium 68 68ga Gozetotide Also Known As Psma 11 Injection , As Been Approved By The Us Food And Drug Administration Fda ,

Telix to Present at Jefferies London Healthcare Conference 2022

MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company),a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that Dr Christian Behrenbruch, Group CEO and Managing Director, will be presenting at the Jefferies London Healthcare Conference 2022. The presentation will take place on Thursday 17 November from 3:15 - 3:45pm GMT (10:15 - 10:45am EST / 2:15 - 2:45am AEDT, 18 Nov). A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff255/tlx/1728648 The webcast will be accessible on demand on the Telix website following the event. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United ....

United States , Kyahn Williamson , Christian Behrenbruch , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Australian Therapeutic Goods Administration , Corporate Communications , Telix Pharmaceuticals Limited , Health Canada , Managing Director , Jefferies London Healthcare Conference , Group Chief Executive , Nov 11 , 022 Prnewswire Telix Pharmaceuticals Limited Asx Tlx , The Company , A Commercial Stage Biopharmaceutical Company Focused On The Development And Commercialisation Of Diagnostic Therapeutic Radiopharmaceuticals , Dvises That Dr Christian Behrenbruch , Group Ceo And Managing Director , Ill Be Presenting At The Jefferies London Healthcare Conference 2022 Presentation Will Take Place On Thursday 17 November From 3 15 45pm Gmt 10 45am Est 2 Aedt , 8 Nova Live Webcast Of The Presentation Will Be Available At Following Link Https Wsw Com Jeff255 Tlx 1728648 Accessible On Demand Telix Website Event About Pharmaceuticals Limited Isa Biopharmaceutical Company Focused Development And Commercialisation Diagnostic Therapeutic Radiopharmaceuticals Is Headquartered In Melbourne , Ustralia With International Operations In The United States , Urope Belgium And Switzerland , Nd Japan Telix Is Developinga Portfolio Of Clinical Stage Products That Aims To Address Significant Unmet Medical Need In Oncology And Rare Diseases Listed On The Australian Securities Exchange Asx Tlx For More Information Visit Www Telixpharma Comand Follow Twitter Linkedin 39s Lead Product , Allium 68 68ga Gozetotide Also Known As Psma 11 Injection , As Been Approved By The Us Food And Drug Administration Fda ,